End-of-day quote
Casablanca S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
980.2
MAD
|
-2.95%
|
|
-3.90%
|
+3.07%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2023
|
2024
|
---|
Capitalization
1 |
2,950
|
2,918
|
3,600
|
7,070
|
7,070
|
Enterprise Value (EV)
1 |
3,117
|
2,918
|
3,889
|
6,847
|
7,070
|
P/E ratio
|
13.6
x
|
13.6
x
|
15.6
x
|
26.1
x
|
21.3
x
|
Yield
|
4.09%
|
-
|
1.05%
|
-
|
-
|
Capitalization / Revenue
|
1,854,305
x
|
-
|
1,989,042
x
|
-
|
-
|
EV / Revenue
|
1,854,306
x
|
-
|
1,989,042
x
|
-
|
-
|
EV / EBITDA
|
10,803,428
x
|
-
|
9,799,863
x
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.7
x
|
-
|
4.25
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,200
|
7,200
|
7,200
|
7,200
|
7,200
|
Reference price
2 |
409.8
|
405.2
|
500.0
|
982.0
|
982.0
|
Announcement Date
|
3/23/19
|
5/1/21
|
4/30/21
|
4/19/24
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2023
|
2024
|
---|
Net sales
|
1,591
|
-
|
1,810
|
-
|
-
|
EBITDA
|
273.1
|
-
|
367.4
|
-
|
-
|
EBIT
|
266
|
-
|
366
|
-
|
-
|
Operating Margin
|
16.72%
|
-
|
20.22%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
217
|
-
|
238.2
|
-
|
-
|
Net margin
|
13.64%
|
-
|
13.16%
|
-
|
-
|
EPS
1 |
30.19
|
29.77
|
32.00
|
36.50
|
46.00
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
16.75
|
-
|
5.250
|
-
|
-
|
Announcement Date
|
3/23/19
|
5/1/21
|
4/30/21
|
4/19/24
|
-
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
198
|
194
|
155
|
289
|
136
|
302
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.8418
x
|
0.7103
x
|
-
|
0.6725
x
|
0.2657
x
|
0.5649
x
|
Free Cash Flow
1 |
46.8
|
57.4
|
102
|
40.2
|
339
|
67.6
|
ROE (net income / shareholders' equity)
|
22.9%
|
29.4%
|
25.4%
|
20.6%
|
22.3%
|
19.6%
|
ROA (Net income/ Total Assets)
|
11.3%
|
12.3%
|
13.6%
|
12.5%
|
13.8%
|
13.1%
|
Assets
1 |
1,325
|
1,766
|
1,571
|
1,835
|
2,014
|
2,032
|
Book Value Per Share
2 |
94.70
|
-
|
124.0
|
163.0
|
180.0
|
197.0
|
Cash Flow per Share
2 |
0.8500
|
-
|
4.240
|
3.570
|
12.20
|
6.240
|
Capex
1 |
59.6
|
48.3
|
31.4
|
59.2
|
62.6
|
70.1
|
Capex / Sales
|
4.21%
|
3.04%
|
1.84%
|
3.29%
|
3.04%
|
3.05%
|
Announcement Date
|
4/9/18
|
2/4/21
|
2/4/21
|
5/1/21
|
4/15/22
|
4/29/23
|
|
1st Jan change
|
Capi.
|
---|
| +3.07% | 701M | | +29.68% | 681B | | +19.77% | 556B | | -4.35% | 361B | | +17.65% | 325B | | +3.77% | 285B | | +13.64% | 235B | | +4.37% | 199B | | -12.11% | 189B | | -3.79% | 157B |
Other Pharmaceuticals
|